Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure

Heart Failure Reviews

Volumn 6, Issue 4, 2001, Pages 341-352

  Krum, Henry ^a   Denver, Rachel ^a   Tzanidis, Alex ^a   Martin, Paul ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Bosentan; Chronic heart failure; Endothelin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; METALLOPROTEINASE; ZINC DERIVATIVE;

BODY FLUID; CLINICAL TRIAL; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EXERCISE TOLERANCE; HEART FAILURE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; LONG TERM CARE; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PLASMA PROTEIN BINDING; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE DIAGNOSIS; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; TREATMENT OUTCOME;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 0034897045     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011416611765     Document Type: Review

References (83)

1. Endothelin as a regulator of cardiovascular function in health and disease
2. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
3. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
4. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
5. Role of endothelin in the exercise intolerance of chronic heart failure
6. Vascular biology of endothelin
7. The paracrine endothelin system: Pathophysiology and implications in clinical medicine
8. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators
9. Structural and functional assessment of small arteries in patients with chronic heart failure
10. Plasma endothelin in congestive heart failure: A predictor of cardiac death?
11. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: Different stimuli for release before and after heart transplantation?
12. Plasma endothelin in chronic heart failure
13. Increased plasma endothelin concentrations in patients with acute heart failure after myocardial infarction
14. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
15. Increased plasma concentrations of endothelin in congestive heart failure in humans
16. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: Endothelin-1 system in the human failing heart
17. Elevated endothelin-1 in heart failure and loss of normal response to postural change
18. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
19. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
20. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
21. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure
22. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation vs patients with sinus rhythm
23. Endothelin in human congestive heart failure
24. Elevated plasma endothelin concentrations in heart failure; An effect of angiotensin II?
25. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1
26. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
27. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
28. Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure
29. Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor, fosinopril
30. Changes in plasma endothelin-1 levels reflect clinical response to beta- blockade in chronic heart failure
31. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells
32. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
33. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure
34. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
35. Biochemical detection of left-ventricular systolic dysfunction
36. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
37. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
38. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
39. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
40. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations
41. How to use natriuretic peptide levels for diagnosis and prognosis
42. Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure
43. Stabilization of human brain natriuretic peptide in blood samples
44. Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature
45. Salivary endothelin and its response to postural changes in humans
46. Salivary endothelin concentrations in the assessment of chronic heart failure
47. The evidence for beta blockers in heart failure
48. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
49. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
50. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
51. The endothelin receptor antagonist SB217242 improves cardiac function and mortality in rat models of heart failure
52. Molecular mechanisms of myocardial remodeling
53. Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats. Effects of chronic angiotensin converting enzyme inhibition
54. Endothelial cell induced modulation of cardiac fibroblast collagen metabolism
55. Effects of endothelins on collagen turnover in cardiac fibroblasts
56. 1
57. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factorbeta synthesis via transcriptional and posttranscriptional mechanisms
58. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats
59. Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide
60. Collagen remodeling after myocardial infarction in the rat heart
61. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
62. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
63. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
64. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators
65. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group
66. Effect of flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study
67. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators
68. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group
69. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: Results of the REACH-1 trial
70. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
71. Contribution of endogenous generation of endothelin-1 to basal vascular tone
72. Endothelins in the normal and diseased kidney
73. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
74. Therapeutic potential of endothelin-converting enzyme inhibitors
75. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin a receptor antagonism
76. Effect of selective endothelin-converting enzyme inhibition on cardiac remodeling early post-myocardial infarction
77. The role of endothelin-converting enzyme-1 in the development of alpha1- adrenergic-stimulated hypertrophy in cultured neonatal rat cardiac myocytes
78. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides
79. Proteolytic processing of big endothelin-3 by the kell blood group protein
80. Neonatal lethality in mice deficient in ECE, a novel member of the endothelin-converting enzyme and neutral endopeptidase family
81. Role of mast cell chymase in the extracellular processing of big- endothelin-1 to endothelin-1 in the perfused rat lung
82. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin
83. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril